

# DTN and endovascular therapy (or getting 30-60-90 off to a good start).

Sept 23, 2016

Tom Jeerakathil BSc, MD, MSc, FRCP(C)  
Professor  
Division of Neurology  
University of Alberta

# Disclosure Statement of Financial Interest


Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation/Financial Relationship	Company
Grant/Research Support Honoraria for 2 ad board meetings	CIHR, CSN, HSFC, IAHS, AHS
Major Stock	BMS Pfizer/ Bayer
Shareholder/Equity	None
Royalty Income	None
Ownership/Founder	None
Intellectual Property Rights	None
Other Financial Benefit	None


# OBJECTIVES

- To discuss what fast DTN needs for fast endovascular


# Timelines in tPA use




# Timelines in tPA use



# Stretcher to CT



# Timelines in tPA use




# The neuron...

In a typical large vessel  
acute ischemic stroke...

1.9 million neurons  
14 billion synapses  
12 km of myelinated  
fibers

are destroyed each  
minute...

(Saver et al, 2006)



5 min ~ 10 million neurons,  
60km of wires


10 min ~ 20 million neurons,  
120km of wires

15 min ~ 30 million neurons,  
180 km of wires...



# Time and outcome

[Lees et al. *Lancet* 2010; 375: 1695–1703]



# Shorter DTN = better outcomes

- Every 15 min drop in DTN associated with a 5% reduction in mortality (OR 0.95;  $p < 0.0001$ )
- Those with DTN < 60 min have reduced risk of intracranial hemorrhage 4.7% vs 5.6%

*Fonarow et al, Circulation 2011, 123:750-758*

# Good is not Good Enough: The Benchmark Stroke Door-to-Needle Time Should be 30 Minutes


*Noreen Kamal, Oscar Benavente, Karl Boyle, Brian Buck, Ken Butcher, Leanne K. Casaubon, Robert Côté, Andrew M Demchuk, Yan Deschaintre, Dar Dowlatshahi, Gordon J Gubitz, Gary Hunter, Tom Jeerakathil, Albert Jin, Eddy Lang, Sylvain Lanthier, Patrice Lindsay, Nancy Newcommon, Jennifer Mandzia, Colleen M. Norris, Wes Oczkowski, Céline Odier, Stephen Phillips, Alexandre Y Poppe, Gustavo Saposnik, Daniel Selchen, Ashfaq Shuaib, Frank Silver, Eric E Smith, Grant Stotts, Michael Suddes, Richard H. Swartz, Philip Teal, Tim Watson, Michael D. Hill*

Figure 3. Secondary Efficacy and Safety Outcomes of Endovascular Therapy vs Standard Therapy

**A** Functional independence (modified Rankin Scale score 0-2) at 90 d

Source	Endovascular Therapy Events/No.	Standard Therapy Events/No.	Odds Ratio (95% CI)
SYNTHESIS, <sup>26</sup> 2013	76/181	84/181	0.84 (0.55-1.27)
MR RESCUE, <sup>27</sup> 2013	12/64	11/54	0.90 (0.36-2.25)
IMS III, <sup>28</sup> 2013	177/415	86/214	1.11 (0.79-1.55)
MR CLEAN, <sup>29</sup> 2015	76/233	51/267	2.05 (1.36-3.09)
ESCAPE, <sup>30</sup> 2015	87/164	43/147	2.73 (1.71-4.37)
EXTEND-IA, <sup>31</sup> 2015	25/35	14/35	3.75 (1.38-10.17)
SWIFT-PRIME, <sup>32</sup> 2015	59/98	33/93	2.75 (1.53-4.94)
REVASCAT, <sup>33</sup> 2015	45/103	29/103	1.98 (1.11-3.53)
Overall	557/1293	351/1094	1.71 (1.18-2.49)


$I^2=75.4\%$ ,  $P<.01$



**B** Mortality at 90 d

Source	Endovascular Therapy Events/No.	Standard Therapy Events/No.	Odds Ratio (95% CI)
SYNTHESIS, <sup>26</sup> 2013	26/181	18/181	1.52 (0.80-2.88)
MR RESCUE, <sup>27</sup> 2013	12/64	13/54	0.73 (0.30-1.76)
IMS III, <sup>28</sup> 2013	83/434	48/222	0.86 (0.58-1.28)
MR CLEAN, <sup>29</sup> 2015	49/233	59/267	0.94 (0.61-1.44)
ESCAPE, <sup>30</sup> 2015	17/164	28/147	0.49 (0.26-0.94)
EXTEND-IA, <sup>31</sup> 2015	3/35	7/35	0.38 (0.09-1.59)
SWIFT-PRIME, <sup>32</sup> 2015	9/98	12/97	0.72 (0.29-1.79)
REVASCAT, <sup>33</sup> 2015	19/103	16/103	1.23 (0.59-2.55)
Overall	218/1312	201/1106	0.87 (0.68-1.12)

$I^2=17.7\%$ ,  $P=.29$



### Treatment details and process times

Treatment with intravenous alteplase	526 (83%)	569 (87%)
Treatment with intravenous alteplase documented within 180 min	442 (70%)	462 (71%)
Process times (min)		
Onset to randomisation	195.5 (142–260)	196 (142–270)*
Onset to intravenous alteplase	100 (75–133)**	100 (74–140)††
Onset to reperfusion	285 (210–362)	NA

Data are median (IQR), n (%), or mean (SD). NIHSS=National Institutes of Health Stroke Scale. ASPECTS=Alberta Stroke Program Early CT Score. \*n=650. †n=631. ‡n=648. §n=620. ¶n=644. ||n=632. \*\*n=598. ††n=618.

**Table 1: Baseline characteristics in the pooled data**

Hermes Metanalysis 2016 Lancet

# The 30-60-90 metric:

- DTN – 30 minutes
- Door to groin puncture 30 minutes
- Groin puncture to recanalization 30 minutes

# Methods- Quality and Process Improvement – now for IA




- Process mapping
  - Fishbone Diagrams, swim lane charts
- PDSA cycles
- Time in motion study
- Case reviews – every lysis assessment every week!
- Intense involvement of administration, stroke neurology

# Methods- Engagement


- Engaging stakeholders
  - Intensive involvement by the ED
  - Diagnostic imaging
- Building relationships
- Education sessions



# Process Mapping For EMS and Triage



# Fishbone Diagram



# Access to endovascular therapy

A


● Comprehensive Stroke Centres

● Primary Stroke Centres

2005



2012




# Access to endovascular therapy

What factors determine the destination primary or comp stroke centre?


- Hospital system?
- Geography/proximity?
- Time (transport and door to treatment)?
- Quality and volume?

PSC  
CSC




# Good Outcome vs. Cost-effectiveness Analysis


Good Outcome





Cost-effectiveness Analysis



- Decision
- DS FLTEVT
  - DS FLTtPA
  - DS GRDEVT
  - DS GRDtPA
  - MS FLT
  - MS GRD



**Stroke CFM**  
**Notes: If this is a HEADS UP call, ensure the caller has the pt ULI, LSN (if known)**



**LOS ANGELES MOTOR SCALE (LAMS)**

	Normal	Right	Left	Total
Facial smile/grimace	┆ (0)	┆ Droop (1)	┆ Droop (1)	
Grip	┆ (0)	┆ Weak grip (1) ┆ No grip (2)	┆ Weak grip (1) ┆ No grip (2)	
Arm strength	┆ (0)	┆ Drifts down (1) ┆ Falls rapidly (2)	┆ Drifts down (1) ┆ Falls rapidly (2)	
<b>TOTAL Score</b>				

---

*‘ In God we trust. All others bring  
data.’*

W. Edwards  
Deming

*‘ Better has no limit.’*



*‘ My message is: get your sh\*t  
together and treat fast.’*

Moyank Goyal

personal  
communication

## Results- Go for the Gold!



# Evolution of a Process needs multiple modifications



**EMERGENCY PROCEDURE**  
For Stroke Emergency Team

**READY**

**S**roke Charge Nurse/Triage Nurse  
EMS - enroute with suspected  
stroke patient

**E**mergency Call 33# – ask for **STROKE  
EMERGENCY TEAM** to be  
paged to **999**- they will not call  
back, just come to ED

**\*\*\*TIME OF PAGE MUST BE RECORDED\*\*\***

**T**eam Stroke Emergency Team  
arrives - await patient's arrival  
and Emergency team initial  
assessment

**GO**

Alberta Health Services



**EMERGENCY PROCEDURE**  
For Stroke Emergency Team

**READY**

**S**roke Charge / Triage RN  
Call :780-445-2215  
Page 999  
The Stroke Fellow will go to A  
Pod  
They will not call Triage back

**\*\*\*TIME OF PAGE MUST BE RECORDED\*\*\***

**E**mergency Transfer Patient to A Pod  
Immediately  
Overhead page "Stroke Patient  
to Area A"

**T**eam Ensure Registration generates  
a CHART STAT

**AVOID Delays**

**GO**

Alberta Health Services

# Key factors

- Pre-notification
- Pre-registration / registration as unknown
- Telestroke 'heads up' to neurologist on arrival with patient information
- Active involvement by ED and Neurology
- Triage – to – CT; 'swarm' at Triage
- tPA in the CT scanner suite (for some)
- Individualized process mapping by site
- Soon - Early activation of transport process – Red referral process

# Key factors

- Do what's necessary to understand the patient (be safe and accurate)
- Avoid unnecessary delay

# SUMMARY

- Fast treatment saves brain, reduces disability and reduces complications
- It takes a systematic approach and buy in from everyone to treat faster
- Our experiences with DTN with help us with EVT

# CONCLUSIONS

## Conclusion

- **30 min DTN is within our grasp!**

- **Faster treatment can lead to better outcomes**

- **Faster DTN could lead to faster endovascular**

## Level of Evidence

- Level C
- Class I, level A
- Class I, level C

**Thank-you!**